# Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

> **NCT07020052** · — · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 33 (estimated)

## Conditions studied

- Maintenance Treatment of Diffuse Midline Gliomas in Children

## Interventions

- **DRUG:** temozolomide/anlotinib/pembrolizumab

## Key facts

- **NCT ID:** NCT07020052
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2030-04-10
- **Final completion:** 2030-07-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020052, "Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07020052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*